Expression of BCRP in Icteric Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00295360|
Recruitment Status : Completed
First Posted : February 23, 2006
Last Update Posted : February 23, 2006
|Condition or disease||Intervention/treatment|
|Icterus||Behavioral: no intervention, pathophysiological study|
BCRP is capable of transport bile acids and may indicate that this transporter is involved in bile acid homeostasis. As an efflux pump, it could protect the enterocytes from potential toxic bile acid concentrations. During cholestasis, where the enterohepatic circulation is disrupted, there occurs an adaptive regulation of transporters for bile acids, bilirubin and cholesterol. These changes take place in liver, kidney, as well as in the intestine.
Using real-time RT-PCR analysis we determine BCRP mRNA expression levels in duodenal tissue of healthy subjects and cholestatic patients. BCRP protein levels will be determined by immunohistochemistry.
Healthy subjects and cholestatic patients are enrolled in the study after giving informed consent. Control subjects with an indication for a gastrointestinal tract endoscopy within a cancer-screening program and patients with obstructive cholestasis with an interventional endoscopic retrograde cholangiopancreatography (ERCP) are included in this study. During endoscopy four biopsy specimens are obtained from the distal part of the duodenum. Biopsies are immediately stored at –70°C until further processing.
|Study Type :||Observational|
|Enrollment :||40 participants|
|Observational Model:||Defined Population|
|Observational Model:||Natural History|
|Official Title:||Influence of Cholestasis on Intestinal BCRP Expression|
|Study Start Date :||June 2003|
|Study Completion Date :||August 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00295360
|University Basel, Department of Research|
|Basel, Basel- Stadt, Switzerland, 4031|
|Principal Investigator:||Jürgen Drewe, MD, MSc||Department of Clinical Pharmacology, University Basel|